Vtesse

Vtesse was a rare disease biotechnology company focused on developing drugs for lysosomal storage disorders. The company's lead program, VTS-270, was a specific formulation of hydroxypropyl-beta-cyclodextrin designed to treat Niemann-Pick Disease Type C1 (NPC1), a fatal genetic disorder. Vtesse was the first company launched by Cydan Development, an orphan drug accelerator, and was established through a collaboration with the National Institutes of Health (NIH). In 2017, the company was acquired by Sucampo Pharmaceuticals for $200 million upfront to bolster its rare disease pipeline. Following the acquisition, the lead asset continued development under Sucampo and later Mallinckrodt, though development was eventually discontinued following Phase 3 results.